Hintergrund: Ziel dieser Studie ist ein Erfahrungsbericht der Augenklinik Jules Gonin über langfristige Ergebnisse der anti-TNF-α-Therapie bei chronischer, nichtinfektiöser Uveitis. Patienten und Methoden: Wir beobachteten Patienten mit chronischer, nichtinfektiöser Uveitis unter systemischer anti-TNF-α-Therapie. Indikation zur anti-TNF-α-Therapie bestand bei fehlendem Ansprechen auf die klassische immunosuppressive Therapie oder in Gegenwart ausgedehnter rheumatischer Erkrankung. Ergebnisse: Fünfzehn Patienten (28 Augen), 7 männliche und 8 weibliche (durchschnittliches Alter: 43 Jahre; Range: 7 bis 70 Jahre) wurden identifiziert. Die Diagnosen umfassten HLA-B27-assoziierte anteriore Uveitis (n = 4), Sarkoidose (n = 2), juvenile idiopathische Arthritis (n = 2), idiopathische retinale Vaskulitis mit begleitender Uveitis (n = 2), Pars planitis (n = 2), M. Adamantiades-Behçet (n = 1), Birdshot-Retinochoroidopathie (n = 1) und M. Crohn (n = 1). Die durchschnittliche Krankheitsdauer betrug 8 Jahre (Range: 1 bis 29 Jahre). Behandlungen wurden mit Infliximab (n = 11), Etanercept (n = 2), oder Adalimumab (n = 2) begonnen. Ein Patient unter Etanercept wurde aufgrund fehlenden Ansprechens auf Infliximab umgestellt. Klinische und angiografische Remission der Uveitis wurde während der ersten zwei Monate bei allen Patienten beobachtet, und hielt während der ganzen Beobachtungsperiode (durchschnittlich: 18 Monate; Range: 3 - 72). Rezidive wurden bei 3 Patienten beobachtet. Diese waren nach Therapieumstellung rückläufig. Nebenwirkungen wurden nur bei einem Patienten nachgewiesen (arterielle Hypotonie). Schlussfolgerungen: In dieser Fallserie mit chronischer, nichtinfektiöser Uveitis zeigte sich die anti-TNF-α-Therapie als effektiv und sicher. Weitere klinische Studien sind nötig, um die geeignete Dauer der Therapie zu bestimmen.
Abstract
Background: The purpose of this study is to describe the experience of Jules Gonin Eye Hospital on the long-term outcome of anti-TNF-α therapy in chronic non-infectious uveitis. Patients and Methods: We identified and followed those patients with chronic non-infectious uveitis who received systemic anti-TNF-α therapy. Anti-TNF-α therapy was administered when no response had been obtained with classical immunosuppressive therapies or in the presence of severe rheumatoid disease. Results: Fifteen patients (28 eyes), 7 male and 8 female (mean age, 43 years; range: 7 to 70 years) were identified. Diagnoses included HLA-B27-associated anterior uveitis (n = 4), sarcoidosis (n = 2), juvenile idiopathic arthritis (n = 2), idiopathic retinal vasculitis with uveitis (n = 2), pars planitis (n = 2), Adamantiades-Behçet disease (n = 1), birdshot retinochoroidopathy (n = 1), and Crohn’s disease (n = 1). Mean duration of ocular disease was 8 years (range: 1 to 29 years). Treatment with infliximab (n = 11), etanercept (n = 2), or adalimumab (n = 2) was initiated. One patient with etanercept was switched to infliximab due to lack of clinical response. Clinical and angiographic regression of uveitis was observed within the first two months of therapy in all patients, and was maintained throughout the entire follow-up period (mean 18 months; range: 3 - 72 months). Recurrence was observed in 3 patients, and resolved after adjustment of therapy. Adverse events were recorded in only one patient (arterial hypotension). Conclusions: In this series of patients with chronic non-infectious uveitis, anti-TNF-α therapy was effective and safe. Further clinical studies are needed to determine an adequate duration of therapy.
3
Vos A F, Haren van M A, Verhagen de C. et al .
Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat.
Invest Ophthalmol Vis Sci.
1994;
35
1100-1106
4
El-Shabrawi Y G, Hermann J.
Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B 27-associated acute anterior uveitis.
Ophthalmology.
2002;
109
2342-2346
5
Fleisher L N, Ferrell J B, McGahan M C.
Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin.
Inflammation.
1990;
14
325-335
6
Foeldvari I, Nielsen S, Kümmerle-Deschner J. et al .
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
J Rheumatol.
2007;
34
1146-1150
7
Galor A, Perez V L, Hammel J P. et al .
Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Ophthalmology.
2006;
113
2317-2323
8
Haraoui B, Cameron L, Ouellet M. et al .
Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
J Rheumatol.
2006;
33
31-36
10
Kavanaugh A, St Clair E W, McCune W J. et al .
Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
J Rheumatol.
2000;
27
841-850
13
Markomichelakis N N, Theodossiadis P G, Pantelia E. et al .
Infliximab for chronic cystoid macular edema associated with uveitis.
Am J Ophthalmol.
2004;
138
648-650
15
Murphy C C, Ayliffe W H, Booth A. et al .
Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
Ophthalmology.
2004;
111
352-356
16
Nakamura S, Yamakawa T, Sugita M. et al .
The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice.
Invest Ophthalmol Vis Sci.
1994;
35
3884-3889
17
Ohno S, Nakamura S, Hori S. et al .
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis.
J Rheumatol.
2004;
31
1362-1368
18
Okada A A, Sakai J, Usui M. et al .
Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats.
Ocul Immunol Inflamm.
1998;
6
111-120
19
Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M. et al .
Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27.
Curr Med Res Opin.
2004;
20
155-157
21
Rosenbaum J T, Howes E L Jr, Rubin R M. et al .
Ocular inflammatory effects of intravitreally-injected tumor necrosis factor.
Am J Pathol.
1988;
133
47-53
22
Santos Lacomba M, Marcos Martin C, Gallardo Galera J M. et al .
Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis.
Ophthalmic Res.
2001;
33
251-255
23
Sfikakis P P, Kaklamanis P H, Elezoglou A. et al .
Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease.
Ann Intern Med.
2004;
140
404-406
24
Sfikakis P P, Theodossiadis P G, Katsiari C G. et al .
Effect of infliximab on sight-threatening panuveitis in Behçet’s disease.
Lancet.
2001;
358
295-296
25
Sobrin L, Kim E C, Christen W. et al .
Infliximab therapy for the treatment of refractory ocular inflammatory disease.
Arch Ophthalmol.
2007;
125
895-900
26
Theodossiadis P G, Markomichelakis N N, Sfikakis P P.
Tumor necrosis factor antagonists: Preliminary evidence for an emerging approach in the treatment of ocular inflammation.
Retina.
2007;
27
399-413
28
Tynjala P, Lindahl P, Honkanen V. et al .
Infliximab and etanecerpt in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Ann Rheum Dis.
2007;
66
548-550
30
Wick M C, Ernestam S, Lindblad S. et al .
Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Scand J Rheumatol.
2005;
34
353-358
